VC Firm Cure Ventures Launches with $350M Life Sciences Fund
Life sciences venture capital firm Cure Ventures has closed its maiden fund – Cure Ventures Fund I – at its targeted hard cap of $350 million to support early-stage companies.
The capital raise was backed by city and state pension funds, a US-based sovereign fund, foundations, endowments and hospital systems, according to the firm.
Founded in 2021 and led by industry veterans Richard Lim, David Fallace and Lou Tartaglia, the Boston-based firm leverages a seed funding model, allowing for de-risking activities, a critical step in the early drug development process, which sets companies up for success in the clinic and beyond.
As part of this process, Cure intends to follow through and co-lead subsequent Series A and B rounds of promising companies, seeing them through to their exits.
The managing partners have played major roles in the success of several breakout biotech companies, including Juno Therapeutics, Agios Therapeutics and Nuvation Bio.
“We founded Cure with a grand ambition: to eradicate life-debilitating and life-ending diseases with curative technologies,” said Fallace, co-founder and managing partner.
